1. Home
  2. SPRO vs AREC Comparison

SPRO vs AREC Comparison

Compare SPRO & AREC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • AREC
  • Stock Information
  • Founded
  • SPRO 2013
  • AREC 2013
  • Country
  • SPRO United States
  • AREC United States
  • Employees
  • SPRO N/A
  • AREC N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • AREC Coal Mining
  • Sector
  • SPRO Health Care
  • AREC Energy
  • Exchange
  • SPRO Nasdaq
  • AREC Nasdaq
  • Market Cap
  • SPRO 45.7M
  • AREC 37.9M
  • IPO Year
  • SPRO 2017
  • AREC 2019
  • Fundamental
  • Price
  • SPRO $0.75
  • AREC $1.29
  • Analyst Decision
  • SPRO Buy
  • AREC Strong Buy
  • Analyst Count
  • SPRO 4
  • AREC 3
  • Target Price
  • SPRO $5.00
  • AREC $4.33
  • AVG Volume (30 Days)
  • SPRO 218.6K
  • AREC 13.7M
  • Earning Date
  • SPRO 05-14-2025
  • AREC 05-20-2025
  • Dividend Yield
  • SPRO N/A
  • AREC N/A
  • EPS Growth
  • SPRO N/A
  • AREC N/A
  • EPS
  • SPRO N/A
  • AREC N/A
  • Revenue
  • SPRO $47,977,000.00
  • AREC $399,962.00
  • Revenue This Year
  • SPRO N/A
  • AREC N/A
  • Revenue Next Year
  • SPRO N/A
  • AREC $3,208.62
  • P/E Ratio
  • SPRO N/A
  • AREC N/A
  • Revenue Growth
  • SPRO N/A
  • AREC N/A
  • 52 Week Low
  • SPRO $0.51
  • AREC $0.38
  • 52 Week High
  • SPRO $1.72
  • AREC $1.68
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 54.69
  • AREC 83.81
  • Support Level
  • SPRO $0.51
  • AREC $0.38
  • Resistance Level
  • SPRO $0.83
  • AREC $0.92
  • Average True Range (ATR)
  • SPRO 0.08
  • AREC 0.16
  • MACD
  • SPRO 0.01
  • AREC 0.09
  • Stochastic Oscillator
  • SPRO 76.85
  • AREC 70.00

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About AREC American Resources Corporation

American Resources Corp is a next-generation, environmentally, and socially responsible supplier of high-quality raw materials to the new infrastructure market. The firm is focused on the extraction and processing of metallurgical carbon, an essential ingredient used in steelmaking, critical and rare earth minerals for the electrification market, and reprocessed metal to be recycled. The firm has a growing portfolio of operations located in the Central Appalachian basin of eastern Kentucky and southern West Virginia where premium quality metallurgical carbon and rare earth mineral deposits are concentrated. Its business model provides a significant opportunity to scale its portfolio of assets to meet the growing global infrastructure and electrification markets.

Share on Social Networks: